ENTA - Enanta adds more than a tenth most in over a year after quarterly results

Enanta Pharmaceuticals (ENTA +14.8%) has recorded the biggest intraday gain since March 2020 after the company issued its Q4 financials for fiscal 2021 on Monday after the close. While revenue slipped ~0.2% YoY to $23.6M missing the consensus, the net loss per share was better than feared on a reported basis. The clinical-stage biotech company reaffirmed its expected timeline to receive data from a study for its Respiratory Syncytial Virus candidate EDP-938 in H1 2022. As previously announced, the company also remains on track to advance its experimental oral COVID-19 therapy EDP-235 into clinical-stage studies in early 2022. Enanta (NASDAQ:ENTA) shares rallied in early October when Merck (NYSE:MRK) said its COVID-19 pill molnupiravir developed with partner Ridgeback Biotherapeutics cut the risk of hospitalization or death by about 50% in a late-stage study involving patients with mild to moderate COVID-19.

For further details see:

Enanta adds more than a tenth, most in over a year after quarterly results